| Phosphorylated RIP3 at Thr231 and Ser232 is a necroptosis‑specific activation state of the receptor‑interacting serine/threonine kinase 3 that marks its assembly into the necrosome and its ability to stably recruit and activate the executioner protein MLKL, placing this double phospho‑form at the core of regulated necrotic cell death downstream of death receptors and pattern recognition receptors. RIP3 belongs to the RIP kinase family and contains an N‑terminal kinase domain, a C‑terminal RIP homotypic interaction motif (RHIM) and intervening regulatory regions; upon stimulation such as TNF‑α in the presence of caspase‑8 inhibition, autophosphorylation and trans‑phosphorylation events within RIP1–RIP3 complexes convert RIP3 into an active kinase, and one key site, Ser227 in human RIP3 (Thr231/Ser232 in mouse RIP3), lies within a conserved segment that is critical for the recruitment and activation of MLKL. Necroptotic signaling proceeds through formation of the amyloid‑like necrosome scaffold composed of RIP1 and RIP3 via RHIM–RHIM interactions, followed by RIP3 homo‑dimerization and oligomerization; RIP3 dimerization triggers intramolecular autophosphorylation at sites including Thr231 and Ser232 in mouse, and phosphorylation of one RIP3 molecule within the dimer is sufficient to promote MLKL binding, showing that these activation‑loop phospho‑residues function as molecular switches for effector engagement. Structural and mutational analyses indicate that phosphorylation of Thr231/Ser232 (corresponding to human T224/S227) synergistically strengthens RIP3 interaction with the MLKL pseudokinase domain and is required for necroptotic cell death even when MLKL can still be phosphorylated, emphasizing that stable recruitment of MLKL to RIP3 and its incorporation into the necrosome depends on this double negative‑charge motif rather than on MLKL phosphorylation alone. Once bound, MLKL is phosphorylated by RIP3 on specific activation‑loop residues, undergoes conformational change and translocates from the cytosol to plasma and intracellular membranes via its four‑helix bundle–brace region, where it disrupts membrane integrity and causes the characteristic swelling and rupture of necroptotic cells, leading to release of intracellular contents and pro‑inflammatory mediators. Thr231/Ser232 phosphorylation of RIP3 is induced in multiple necroptosis models and is inhibited by RIP1 kinase inhibitors such as Nec‑1, consistent with RIP1 acting upstream to initiate RIP3 phosphorylation, and phospho‑specific antibodies recognizing mouse RIP3 Thr231/Ser232 are widely used to detect necroptosis activation and necrosome formation in tissues and experimental systems. RIP3‑mediated necroptosis with Thr231/Ser232 phosphorylation participates in diverse pathological processes, including ischemia–reperfusion injury, neurodegeneration, viral and bacterial infections and inflammatory diseases, and reviews of RIPK3 signaling highlight that aberrant or sustained activation of this pathway contributes to tissue damage and chronic inflammation, while pharmacologic or genetic blockade of RIP3 phosphorylation reduces necroptotic cell death and ameliorates disease phenotypes in preclinical models. |
